A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Glucose‐dependent insulinotropic polypeptide (GIP) is secreted postprandially and acts in concert with glucose to stimulate insulin secretion from the pancreas. Here, we describe a novel pathway for the regulation of GIP receptor (GIPR) expression within clonal β‐cell lines, pancreatic islets, and in vivo . High (25 mM) glucose was able to significantly reduce GIPR mRNA levels in INS(832/13) cells after only 6 h. In contrast, palmitic acid (2 mM) and WY 14643 (100 μM) stimulated approximate doublings of GIPR expression in INS(832/13) cells under low (5.5 mM), but not high (25 mM), glucose conditons, suggesting that fat can regulate GIPR expression via PPARα in a glucose‐dependent manner. Both MK‐886, an antagonist of PPARα, and a dominant negative form of PPARα transfected into INS(832/13) cells caused a significant reduction in GIPR expression in low, but not high, glucose conditions. Finally, in hyperglycemic clamped rats, there was a 70% reduction in GIPR expression in the islets and a 71% reduction in GIP‐stimulated insulin secretion from the perfused pancreas. Thus, evidence is presented that the GIPR is controlled at normoglycemia by the fatty acid load on the islet; however, when exposed to hyperglycemic conditions, the GIPR is down‐regulated, which may contribute to the decreased responsiveness to GIP that is observed in type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, GLP-1 and GIP mediate insulin secretion and concomitantly, insulin modulates GIP212 and GLP-1 release; the latter ocurring through the PI3K/Akt- and mitogen-activated protein kinase kinase (MAPKK or MEK)/ERK1/2 pathway.213”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [212]
Citations
Cites
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Desvergne, B. (1999) · Endocrine Reviews · doi:10.1210/er.20.5.649 · Cited by 1,251
Kulkarni, R. N., Brüning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A., & Kahn, C. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80546-2 · Cited by 1,148
Quantitative RT-PCR: Pitfalls and Potential
Freeman, W. M., Walker, S. J., & Vrana, K. E. (1999) · BioTechniques · doi:10.2144/99261rv01 · Cited by 1,147
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 3×
“Glucose-dependent insulinotropic polypeptide (GIP) and the proglucagon gene products glucagon-like peptide-1-( 7-37 ) (GLP-1) and GLP-1-(7-36)-amide are the major incretins that act via this endocrine system (1).”
BackgroundMethodSelf-citationHohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., & Newgard, C. B. (2000) · Diabetes · doi:10.2337/diabetes.49.3.424 · Cited by 917
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 4×
“Both GIPR and GLP-1 receptor null mice displayed compromised insulin secretion and therefore exhibited poor glucose tolerance to an oral glucose load (8, 9).”
BackgroundInfluentialMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 4×
“Both GIPR and GLP-1 receptor null mice displayed compromised insulin secretion and therefore exhibited poor glucose tolerance to an oral glucose load (8, 9).”
BackgroundInfluential
Research works printed but not linked: 2
- 10.1210/en.140.1.398 · doi:10.1210/en.140.1.398 · Paper page
- 10.1042/bj3560899 · doi:10.1042/bj3560899 · Paper page
Cited by
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Another study suggested a role for circulating free fatty acids in down-regulation of GIPR expression (Lynn et al., 2003).”
BackgroundGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The molecular mechanism that supports this differential insulinotropic response in type 2 diabetes is not known, but purported prospects include downregulation in GIP receptor signaling (402, 403, 495, 670, 678) and alternative splicing of the GIP receptor in hyperglycemia (261).”
BackgroundMaida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 294
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 288
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
Deacon, C. F., Ahrén, B., & Holst, J. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1091 · Cited by 194
Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
McIntosh, C. H. S., Demuth, H.-U., Pospisilik, J. A., & Pederson, R. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.001 · Cited by 192
Self-citationIncretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Yabe, D., & Seino, Y. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.010 · Cited by 188
Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S., & Kim, S. (2009) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 171
Self-citationEhses, J. A., Casilla, V. R., Doty, T., Pospisilik, J. A., Winter, K. D., Demuth, H.-U., Pederson, R. A., & McIntosh, C. H. S. (2003) · Endocrinology · doi:10.1210/en.2002-0068 · Cited by 159
Self-citationTherapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
Baggio, L. L., & Drucker, D. J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.110104.115624 · Cited by 149
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130
Self-citationLalloyer, F., Vandewalle, B., Percevault, F., Torpier, G., Kerr-Conte, J., Oosterveer, M., Paumelle, R., Fruchart, J.-C., Kuipers, F., Pattou, F., et al. (2006) · Diabetes · doi:10.2337/db06-0016 · Cited by 114
Malavazos, A. E., Iacobellis, G., Dozio, E., Basilico, S., Di Vincenzo, A., Dubini, C., Menicanti, L., Vianello, E., Meregalli, C., Ruocco, C., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad050 · Cited by 100
Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., & Hirano, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035683 · Cited by 96
Incretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 105
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 113
K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease
Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 110
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
Cho, Y. M., & Kieffer, T. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1986-3 · Cited by 98
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 85
Meier, J. J., Gallwitz, B., Kask, B., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s220 · Cited by 85
Genetically engineered pig models for diabetes research
Wolf, E., Braun-Reichhart, C., Streckel, E., & Renner, S. (2013) · Transgenic Research · doi:10.1007/s11248-013-9755-y · Cited by 98
A novel GIP receptor splice variant influences GIP sensitivity of pancreatic β-cells in obese mice
Harada, N., Yamada, Y., Tsukiyama, K., Yamada, C., Nakamura, Y., Mukai, E., Hamasaki, A., Liu, X., Toyoda, K., Seino, Y., et al. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00358.2007 · Cited by 79
Rajan, S., Dickson, L. M., Mathew, E., Orr, C. M. O., Ellenbroek, J. H., Philipson, L. H., & Wicksteed, B. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.010 · Cited by 77
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets
Zhou, J., Livak, M. F. A., Bernier, M., Muller, D. C., Carlson, O. D., Elahi, D., Maudsley, S., & Egan, J. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00070.2007 · Cited by 73
GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women
Rudovich, N. N., Kaiser, S., Engeli, S., Osterhoff, M. A., Gögebakan, Ö., Blüher, M., & Pfeiffer, A. F. H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.02.006 · Cited by 74
Berglund, L. M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K., Alkayyali, S., Brøns, C., Forsblom, C., Jonsson, A., et al. (2016) · Diabetes · doi:10.2337/db15-0122 · Cited by 65
Whitaker, G. M., Lynn, F. C., McIntosh, C. H. S., & Accili, E. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032675 · Cited by 64
Self-citationIn Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update
Kury, L. T. A., Abdoh, A., Ikbariah, K., Sadek, B. S., & Mahgoub, M. (2021) · Molecules · doi:10.3390/molecules27010182 · Cited by 78
Lampron, A., Bourdeau, I., Hamet, P., Tremblay, J., & Lacroix, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0221 · Cited by 61
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012203 · Cited by 58
Self-citationGlucose‐dependent insulinotropic polypeptide signaling in pancreatic β‐cells and adipocytes
McIntosh, C. H., Widenmaier, S., & Kim, S. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00196.x · Cited by 57
Self-citationAn Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus
Mahgoub, M., Ali, I. I., Adeghate, J. O., Tekes, K., Kalász, H., & Adeghate, E. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119328 · Cited by 74
Figueiredo, C. P., Pamplona, F. A., Mazzuco, T. L., Aguiar, A. S., Walz, R., & Prediger, R. D. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833c8544 · Cited by 62
Kang, Z. F., Deng, Y., Zhou, Y., Fan, R. R., Chan, J. C. N., Laybutt, D. R., Luzuriaga, J., & Xu, G. (2013) · Diabetologia · doi:10.1007/s00125-012-2776-x · Cited by 54
Aaboe, K., Knop, F. K., Vilsboll, T., Vølund, A., Simonsen, U., Deacon, C. F., Madsbad, S., Holst, J. J., & Krarup, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1731 · Cited by 53
Gupta, D., Peshavaria, M., Monga, N., Jetton, T. L., & Leahy, J. L. (2010) · Diabetes · doi:10.2337/db09-1655 · Cited by 47
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 51
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
“In the same studies, exposure of INS1E cells to gluco-toxicity was found to decrease Gipr expression [42].”
InfluentialGabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 37
Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review
Wani, J. H., John‐Kalarickal, J., & Fonseca, V. A. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.06.008 · Cited by 37
The contribution of incretin hormones to the pathogenesis of type 2 diabetes
Meier, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.007 · Cited by 46
Vahl, T. P., & D’Alessio, D. A. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000078991.96795.84 · Cited by 33
Maekawa, R., Ogata, H., Murase, M., Harada, N., Suzuki, K., Joo, E., Sankoda, A., Iida, A., Izumoto, T., Tsunekawa, S., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00352.2017 · Cited by 28
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
Chang, C.-Y., Kanthimathi, M. S., Tan, A. T. B., Nesaretnam, K., & Teng, K. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1307-9 · Cited by 27
Incretin hormones as immunomodulators of atherosclerosis
Alonso, N., Julián, M. T., Puig‐Domingo, M., & Vives‐Pi, M. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00112 · Cited by 25
Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases
da Silva, E. M., Yariwake, V. Y., Alves, R. W., de Araújo, D. R., & Andrade‐Oliveira, V. (2022) · Peptides · doi:10.1016/j.peptides.2022.170834 · Cited by 18
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
Davies, I., Adriaenssens, A. E., Scott, W. R., Carling, D., Murphy, K. G., MINNION, J. S., Bloom, S. R., Jones, B. J., & Tan, T. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102094 · Cited by 20
Pathak, V., Vasu, S., Flatt, P. R., & Irwin, N. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12227 · Cited by 19
Metformin: Expanding the Scope of Application—Starting Earlier than Yesterday, Canceling Later
Kononova, Y. A., Likhonosov, N. P., & Babenko, A. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042363 · Cited by 18
Daley, E. J., Pajevic, P. D., Roy, S., & Trackman, P. C. (2019) · JBMR Plus · doi:10.1002/jbm4.10212 · Cited by 19
García‐Jiménez, C. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00014-x · Cited by 15
Sawamura, T., Mizoguchi, R., Ohmori, A., Kometani, M., Yoneda, T., & Karashima, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01472-w · Cited by 18
Food Intake Affects Sperm-Egg Fusion Through the GIP/PSG17 Axis in Mice
Shimizu, T., Sato, T. K., Tsukiyama, K., Fujita, H., Kato, S., Hoizumi, M., Shirasawa, H., Narita, T., Terada, Y., Seino, Y., et al. (2017) · Endocrinology · doi:10.1210/en.2016-1861 · Cited by 11
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Yang, G., Liang, X., Jiang, Y., Li, C., Zhang, Y., Zhang, X., Chang, X., Shen, Y., & Meng, X. (2022) · Aquaculture Nutrition · doi:10.1155/2022/4330251 · Cited by 7
Tajima, K., Shirakawa, J., Togashi, Y., Inoue, H., Sato, K., Orime, K., Ito, Y., Kaji, M., Sakamoto, E., Nakamura, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064633 · Cited by 8
Rees, T. A., Buttle, B., Tasma, Z., Yang, S.-H., Harris, P. W. R., & Walker, C. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1463313 · Cited by 9
Puddu, A., Sanguineti, R., Montecucco, F., & Viviani, G. L. (2015) · Journal of Diabetes Research · doi:10.1155/2015/326359 · Cited by 7
Nauck, M. A., Holle, H., Kahle, M., Tytko, A., Deacon, C. F., Holst, J. J., & Meier, J. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170176 · Cited by 5
The Contribution of Enteroinsular Hormones to the Pathogenesis of Type 2 Diabetes Mellitus
Diab, D. L., & D’Alessio, D. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0114-6 · Cited by 8
Genetically Tailored Pig Models for Translational Biomedical Research
Aigner, B., Keßler, B., Klymiuk, N., Kurome, M., Renner, S., Wünsch, A., & Wolf, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00026-7 · Cited by 5
Incretins and Regulation of Insulin Secretion
Nauck, M. A., & Meier, J. J. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_17 · Cited by 4
The Role of Incretins in Insulin Secretion
Schroeder, B. E., & Kolterman, O. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_4 · Cited by 3
Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes
McIntosh, C. H. S., Kim, S. ‐., Pederson, R. A., Heiser, U. F., & Demuth, H. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch12 · Cited by 3
Self-citationMetformin in prediabetes: key mechanisms for the prevention of diabetes and cardiometabolic risks
Babenko, A. Y. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-10-96-103 · Cited by 2
Winkler, G. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29237 · Cited by 1
Gastric inhibitory polypeptide receptor
Hoersch, D., & Schrader, J. (2007) · AfCS-Nature Molecule Pages · doi:10.1038/mp.a001028.01 · Cited by 1
Genetically Tailored Pig Models for Translational Biomedical Research
Aigner, B., Keßler, B., Klymiuk, N., Kurome, M., Renner, S., Wünsch, A., & Wolf, E. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00032-4 · Cited by 1
Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus
Yoo, S., Yang, E.-J., & Koh, G. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0105 · Cited by 2
Hinke, S. A., Pederson, R. A., & McIntosh, C. H. S. (2006) · Springer eBooks · doi:10.1007/0-387-32824-6_13 · Cited by 1
Self-citationNutrigenomics, β-Cell Function and Type 2 Diabetes
Nino‐Fong, R., Collins, T., & Chan, C. B. (2007) · Current Genomics · doi:10.2174/138920207780076947 · Cited by 4
AMPK and TET2 Signaling Pathway and their Natural ActivatorsPreprint
Patil, S., Sharma, R., Sharma, U. K., & Padwad, Y. S. (2022) · Preprints.org · doi:10.20944/preprints202204.0100.v1
Module 18. Update on pharmacological options in the management of type 2 diabetes
Meetoo, D. D. (2012) · Nurse Prescribing · doi:10.12968/npre.2012.10.12.cpd3
Perfil de expressão de genes modulados pela amilina em ilhotas pancreáticas de rato
de Oliveira, L. S. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2009.tde-25062009-092443
Widenmaier, S. B. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071070
Module 8. The Management of Type 2 Diabetes: Pharmacological Options
Meetoo, D. D. (2010) · Nurse Prescribing · doi:10.12968/npre.2010.8.12.cpd1
Luseogliflozin restores GIP responsiveness in diabetic male mice with preserved β‐cell function
Yingyue, Q., Takahashi, H., Yokoi, N., Ogawa, W., & Sugawara, K. (2026) · Physiological Reports · doi:10.14814/phy2.71016
Metadata
- Authors
- Lynn, F. C., Thompson, S. A., Pospisilik, J. A., Ehses, J. A., Hinke, S. A., Pamir, N., McIntosh, C. H. S., & Pederson, R. A.
- Affiliations
- University of British Columbia (CA)
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2002-11-15
- Volume
- 17
- Issue
- 1
- Pages
- 91-93
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1967225560
- Cited by
- 91
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 1 · 2020: 2 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 3 · 2013: 5 · 2012: 6
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Diabetes Association
- Canada Foundation for Innovation
- Health Research Foundation
- Medical Research Council
- Killam Trusts
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, beta-cell gene expression, PPARα, palmitic acid, fatty acid regulation, hyperglycemia, insulin secretion, type 2 diabetes, Wy-14,643, MK-886, pancreatic islets
- MeSH terms
- Animals, Cell Line, Dose-Response Relationship, Drug, Fatty Acids, Gene Expression Regulation, Glucose, Islets of Langerhans, Kinetics, Models, Biological, Rats, Zucker, Receptors, Gastrointestinal Hormone, RNA, Messenger, Transcription Factors, Transcription, Genetic, Signal Transduction, Down-Regulation, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.